Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Revenue of top 20 respiratory brands in the U.S. 2016

Top 20 respiratory brands in the U.S. based on revenue in 2016 (in million U.S. dollars)

by Matej Mikulic, last edited Apr 26, 2017
Revenue of top 20 respiratory brands in the U.S. 2016 This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Show more

Top 20 respiratory brands in the U.S. based on revenue in 2016 (in million U.S. dollars)

Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Matej Mikulic, last edited Apr 26, 2017
This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Asthma in the U.S.
Asthma in the U.S.

All Information
in one Presentation

Asthma in the U.S.

Everything On "Asthma in the U.S." in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Asthma in the U.S."
  • Prevalence
  • Asthma attacks
  • Deaths
  • Regions and states
  • Doctors and hospitals
  • Medication
The most important statistics
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.